Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

ABSTRACT:

Objective

Impulse control disorders (ICDs) in Parkinson disease (PD) are common and can be difficult to manage. The objective of this study was to determine the efficacy and tolerability of naltrexone, an opioid antagonist, for the treatment of ICDs in PD.

Methods

Patients with PD (n = 50) and an ICD were enrolled in an 8-week, randomized (1:1), double-blind, placebo-controlled study of naltrexone 50-100 mg/d (flexible dosing). The primary outcome measure was response based on the Clinical Global Impression-Change score, and the secondary outcome measure was change in symptom severity using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) ICD score.

Results

Forty-five patients (90%) completed the study. The Clinical Gl

SUBMITTER: Papay K 

PROVIDER: S-EPMC4155050 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature